Vor Bio Doses First Patient in Phase 3 Sjögren’s Trial
RemeGen’s prior Phase 3 study in China of telitacicept in primary Sjögren’s disease reported statistically significant and clinically meaningful...
ZUSDURI Delivers 72.2% Durable Response in enVision Trial
ZUSDURI delivered a 79.6% complete response at three months in the pivotal Phase 3 ENVISION study, with a Kaplan-Meier–estimated...
Quantum, Allucent Advance Phase 2 Multiple Sclerosis Trial
Quantum BioPharma has signed a binding letter of intent with Allucent to run a planned Phase 2 study of...
RenovoRx TIGeR-PaC Trial Surpasses 100 Patient Milestone
As of March 24, 2026, RenovoRx’s Phase III TIGeR-PaC trial in locally advanced pancreatic cancer has randomized 104 of...
Tonix Starts Phase 1 Trial for New Migraine Pain Treatment
Tonix Pharmaceuticals has dosed the first participant in an investigator-initiated Phase 1 study of TNX-1900, an intranasal, magnesium-potentiated oxytocin...
ORIC to Report Rinzimetostat Dose Data from mCRPC Trial
ORIC will detail combination dose optimization findings from its Phase 1b study of rinzimetostat (ORIC-944) in metastatic castration-resistant prostate...
The POLAR Trial Proves Pancreatic Cancer Trials Were Broken by Design
The POLAR trial's Phase 2 results in homologous-recombination-deficient metastatic pancreatic cancer aren't just a clinical win — they're an...
GlucoTrack Targets Early Q2 For US FDA Clinical Trial Filing
Glucotrack’s first-in-human study of its fully implantable continuous blood glucose monitor reported a Mean Absolute Relative Difference of 7.7%...
First Patient Dosed in RAD 402 Advanced Prostate Cancer Trial
Radiopharm Theranostics has dosed the first patient in its first-in-human Phase 1 trial of RAD 402 in advanced prostate...
Biogen Drug Shows Promise in Phase 2 Cutaneous Lupus Trial
Litifilimab achieved clear or almost clear skin in 14.7% of patients at Week 16 versus 2.9% on placebo in...